STAAR Surgical Company (STAA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by STAAR Surgical Company on September 9, 2026. The report discloses the appointment of a new senior executive officer and related compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation details.
Material Changes and Executive Appointment
On September 8, 2026, the Company appointed David Bailey as Chief Commercial Officer, effective immediately. Mr. Bailey previously served as the Company's CEO & President (2001–2008) and President, International Operations (2008–2011). Since 2010, he has been the Founder and President of DB Consulting, a firm that has provided strategic advisory services to the Company.
Compensatory Arrangements
- Base Salary: CHF 462,825 annually (approximately $575,000), prorated for 2026.
- Annual Cash Bonus: Target of 60% of base salary for fiscal 2026, prorated.
- Initial Equity Grant: Restricted Stock Units (RSUs) valued at $850,000, vesting over three years (one-third annually).
- 2026 Long-Term Incentive: Award valued at $1,400,000, prorated, consisting of 50% stock options and 50% RSUs.
- Other Benefits: Participation in standard executive compensation, benefits, severance, and change in control plans.
Outlook, Risks, and Contingencies
The filing does not provide updated financial guidance, outlook, or specific risk factors beyond the standard disclosure that the information is not deemed "filed" under Section 18 of the Exchange Act. The appointment is intended to support strategic planning, operational improvement, and market expansion.
Key Facts for Investor Verification
- Verify the exact vesting schedule and performance conditions for the $1,400,000 long-term incentive award in the attached Offer Letter (Exhibit 10.1).
- Confirm the total number of shares underlying the RSU and stock option grants based on the current stock price at the time of grant.
- Review the full text of the Bailey Agreement for specific terms regarding severance and change in control provisions.
- Assess the strategic impact of re-engaging a former CEO as Chief Commercial Officer on the Company's growth strategy.